 |
10 Products |  |
2 Diseases | | 10 Products |
|
20 Trials |  |
746 News |  |
| «12345678910111213» |
- | ezutromid (SMT C1100) / Sarepta Therap
Enrollment closed: Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - Jun 14, 2017
P2, N=40, Active, not recruiting, Sponsor: Summit Therapeutics
Enrolling by invitation --> Active, not recruiting
- | Exondys 51 (eteplirsen) / Sarepta Therap
Enrollment closed: Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy (clinicaltrials.gov) - Jun 2, 2017
P2, N=40, Active, not recruiting, Sponsor: Sarepta Therapeutics
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Exondys 51 (eteplirsen) / Sarepta Therap
Enrollment closed: PROMOVI: Study of Eteplirsen in DMD Patients (clinicaltrials.gov) - Jun 2, 2017
P3, N=160, Active, not recruiting, Sponsor: Sarepta Therapeutics
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
New P2 trial, P2 data: GOOD-IDES: Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (clinicaltrials.gov) - May 17, 2017
P2, N=15, Recruiting, Sponsor: Mårten Segelmark
- ezutromid (SMT C1100) / Sarepta Therap
Enrollment status, Trial primary completion date: Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - Apr 14, 2017
P2, N=40, Enrolling by invitation, Sponsor: Summit Therapeutics
Recruiting --> Active, not recruiting Recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2017 --> Jun 2018
- Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
Trial termination, Trial primary completion date: IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients (clinicaltrials.gov) - Jan 19, 2017
P2, N=2, Terminated, Sponsor: Hansa Medical AB
Recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2017 --> Jun 2018 Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Jan 2017; Sponsor review of initial results demonstrates a non-favourable risk benefit
- Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
Trial completion: Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation (clinicaltrials.gov) - Jan 12, 2017
P2, N=10, Completed, Sponsor: Hansa Medical AB
Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Jan 2017; Sponsor review of initial results demonstrates a non-favourable risk benefit Active, not recruiting --> Completed
- Elevidys (delandistrogene moxeparvovec) / Sarepta Therap, Roche
Enrollment closed: Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Nov 22, 2016
P1, N=2, Active, not recruiting, Sponsor: Jerry R. Mendell
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- Galgt2 gene therapy / Nationwide Children's, Sarepta Therap
Trial withdrawal: Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2 (clinicaltrials.gov) - Nov 7, 2016
P1, N=0, Withdrawn, Sponsor: Kevin Flanigan
Enrolling by invitation --> Active, not recruiting Recruiting --> Withdrawn
- Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
Trial primary completion date, Post-transplantation: Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation (clinicaltrials.gov) - Oct 11, 2016
P1/2, N=20, Recruiting, Sponsor: Cedars-Sinai Medical Center
Recruiting --> Withdrawn Trial primary completion date: Apr 2016 --> Aug 2018
- Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
Enrollment open: IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients (clinicaltrials.gov) - Sep 6, 2016
P2, N=6, Recruiting, Sponsor: Hansa Medical AB
Trial primary completion date: Apr 2016 --> Aug 2018 Not yet recruiting --> Recruiting
- | ezutromid (SMT C1100) / Sarepta Therap
New P2 trial: Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - Aug 8, 2016
P2, N=40, Recruiting, Sponsor: Summit Therapeutics
- |||||| Vyondys 53 (golodirsen) / Sarepta Therap, Amondys 45 (casimersen) / Sarepta Therap
Enrollment open: ESSENCE: Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - Aug 3, 2016
P3, N=99, Recruiting, Sponsor: Sarepta Therapeutics
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
New P2 trial: IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients (clinicaltrials.gov) - Aug 3, 2016
P2, N=6, Not yet recruiting, Sponsor: Hansa Medical AB
- | Vyondys 53 (golodirsen) / Sarepta Therap
Enrollment closed: Phase I/II Study of SRP-4053 in DMD Patients (clinicaltrials.gov) - Jul 28, 2016
P1/2, N=39, Active, not recruiting, Sponsor: Sarepta Therapeutics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Galgt2 gene therapy / Nationwide Children's, Sarepta Therap
Enrollment open: Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2 (clinicaltrials.gov) - Jul 18, 2016
P1, N=3, Recruiting, Sponsor: Kevin Flanigan
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
Enrollment open, P2 data: A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test (clinicaltrials.gov) - Jul 14, 2016
P2, N=15, Recruiting, Sponsor: Hansa Medical AB
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Vyondys 53 (golodirsen) / Sarepta Therap, Amondys 45 (casimersen) / Sarepta Therap
Trial primary completion date: ESSENCE: Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - Jun 20, 2016
P3, N=99, Not yet recruiting, Sponsor: Sarepta Therapeutics
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2018 --> Sep 2019
- Vyondys 53 (golodirsen) / Sarepta Therap
Trial primary completion date: Phase I/II Study of SRP-4053 in DMD Patients (clinicaltrials.gov) - Jun 5, 2016
P1/2, N=48, Recruiting, Sponsor: Sarepta Therapeutics
Trial primary completion date: Apr 2018 --> Sep 2019 Trial primary completion date: Jan 2017 --> May 2019
- | Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
New P2 trial, P2 data: A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test (clinicaltrials.gov) - Jun 4, 2016
P2, N=15, Not yet recruiting, Sponsor: Hansa Medical AB
- Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
Enrollment closed: Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation (clinicaltrials.gov) - May 25, 2016
P2, N=8, Active, not recruiting, Sponsor: Hansa Medical AB
Trial primary completion date: Jan 2017 --> May 2019 Recruiting --> Active, not recruiting
- |||| Exondys 51 (eteplirsen) / Sarepta Therap
Trial primary completion date: PROMOVI: Study of Eteplirsen in DMD Patients (clinicaltrials.gov) - Apr 7, 2016
P3, N=160, Recruiting, Sponsor: Sarepta Therapeutics
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2018 --> Jan 2019
- Vyondys 53 (golodirsen) / Sarepta Therap
Trial primary completion date: Phase I/II Study of SRP-4053 in DMD Patients (clinicaltrials.gov) - Mar 30, 2016
P1/2, N=48, Recruiting, Sponsor: Sarepta Therapeutics
Trial primary completion date: Jan 2018 --> Jan 2019 Trial primary completion date: May 2018 --> Jan 2017
- Galgt2 gene therapy / Nationwide Children's, Sarepta Therap
New P1 trial: Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2 (clinicaltrials.gov) - Mar 10, 2016
P1, N=3, Not yet recruiting, Sponsor: Kevin Flanigan
- ||||| Vyondys 53 (golodirsen) / Sarepta Therap, Amondys 45 (casimersen) / Sarepta Therap
Trial initiation date: ESSENCE: Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - Feb 29, 2016
P3, N=99, Not yet recruiting, Sponsor: Sarepta Therapeutics
Trial primary completion date: May 2018 --> Jan 2017 Initiation date: Feb 2016 --> Jun 2016
- | Amondys 45 (casimersen) / Sarepta Therap
Enrollment closed, Metastases: Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients (clinicaltrials.gov) - Dec 11, 2015
P1/2, N=12, Active, not recruiting, Sponsor: Sarepta Therapeutics
Initiation date: Feb 2016 --> Jun 2016 Recruiting --> Active, not recruiting
- Vyondys 53 (golodirsen) / Sarepta Therap
Trial primary completion date: Phase I/II Study of SRP-4053 in DMD Patients (clinicaltrials.gov) - Nov 17, 2015
P1/2, N=48, Recruiting, Sponsor: Sarepta Therapeutics
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> May 2018
- | Amondys 45 (casimersen) / Sarepta Therap
Enrollment open, Metastases: Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=12, Recruiting, Sponsor: Sarepta Therapeutics
Trial primary completion date: Dec 2016 --> May 2018 Not yet recruiting --> Recruiting
- | ezutromid (SMT C1100) / Sarepta Therap
Trial completion: Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet (clinicaltrials.gov) - Aug 27, 2015
P1, N=12, Completed, Sponsor: Summit Therapeutics
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Exondys 51 (eteplirsen) / Sarepta Therap
Trial primary completion date: PROMOVI: Study of Eteplirsen in DMD Patients (clinicaltrials.gov) - Aug 26, 2015
P3, N=160, Recruiting, Sponsor: Sarepta Therapeutics
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Jan 2018
- | Amondys 45 (casimersen) / Sarepta Therap
New P1/2 trial, Metastases: Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients (clinicaltrials.gov) - Aug 21, 2015
P1/2, N=12, Not yet recruiting, Sponsor: Sarepta Therapeutics
- Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
Enrollment open: Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation (clinicaltrials.gov) - Jul 18, 2015
P2, N=8, Recruiting, Sponsor: Hansa Medical AB
Trial primary completion date: May 2016 --> Jan 2018 Not yet recruiting --> Recruiting
- || Vyondys 53 (golodirsen) / Sarepta Therap, Amondys 45 (casimersen) / Sarepta Therap
New P3 trial: ESSENCE: Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - Jul 16, 2015
P3, N=99, Not yet recruiting, Sponsor: Sarepta Therapeutics
- Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
New P2 trial: Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation (clinicaltrials.gov) - Jun 18, 2015
P2, N=8, Not yet recruiting, Sponsor: Hansa Medical AB
- Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
Enrollment open, Post-transplantation: Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation (clinicaltrials.gov) - Jun 18, 2015
P1/2, N=20, Recruiting, Sponsor: Cedars-Sinai Medical Center
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ezutromid (SMT C1100) / Sarepta Therap
Enrollment closed: Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet (clinicaltrials.gov) - Jun 15, 2015
P1, N=12, Active, not recruiting, Sponsor: Summit Therapeutics
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Exondys 51 (eteplirsen) / Sarepta Therap
Enrollment open: Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy (clinicaltrials.gov) - May 17, 2015
P2, N=40, Recruiting, Sponsor: Sarepta Therapeutics
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
New P1/2 trial, Post-transplantation: Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation (clinicaltrials.gov) - Apr 27, 2015
P1/2, N=20, Active, not recruiting, Sponsor: Cedars-Sinai Medical Center
- | Exondys 51 (eteplirsen) / Sarepta Therap
New P2 trial: Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy (clinicaltrials.gov) - Apr 17, 2015
P2, N=40, Not yet recruiting, Sponsor: Sarepta Therapeutics
- Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
Trial completion, P2 data: Phase II Study, Evaluation of Safety and Efficacy of Immunoglobulin G Degrading Enzyme of Streptococcus Pyogenes (IdeS) in Chronic Kidney Disease (clinicaltrials.gov) - Mar 18, 2015
P2, N=8, Completed, Sponsor: Hansa Medical AB
Not yet recruiting --> Recruiting Recruiting --> Completed
- | ezutromid (SMT C1100) / Sarepta Therap
New P1 trial: Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet (clinicaltrials.gov) - Mar 9, 2015
P1, N=12, Recruiting, Sponsor: Summit Corporation Plc.
- Elevidys (delandistrogene moxeparvovec) / Sarepta Therap, Roche
New P1 trial: Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Mar 3, 2015
P1, N=6, Enrolling by invitation, Sponsor: Jerry R. Mendell
- | Vyondys 53 (golodirsen) / Sarepta Therap
Enrollment open: Phase I/II Study of SRP-4053 in DMD Patients (clinicaltrials.gov) - Jan 7, 2015
P1/2, N=48, Recruiting, Sponsor: Sarepta Therapeutics
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Exondys 51 (eteplirsen) / Sarepta Therap
Enrollment open, Metastases: Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy (clinicaltrials.gov) - Dec 10, 2014
P2, N=20, Recruiting, Sponsor: Sarepta Therapeutics
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Vyondys 53 (golodirsen) / Sarepta Therap
New P1/2 trial: Phase I/II Study of SRP-4053 in DMD Patients (clinicaltrials.gov) - Dec 8, 2014
P1/2, N=48, Recruiting, Sponsor: Sarepta Therapeutics
- | Exondys 51 (eteplirsen) / Sarepta Therap
Enrollment closed, Metastases: Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy (clinicaltrials.gov) - Nov 24, 2014
P2, N=20, Active, not recruiting, Sponsor: Sarepta Therapeutics
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Exondys 51 (eteplirsen) / Sarepta Therap
New P2 trial, Metastases: Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy (clinicaltrials.gov) - Nov 11, 2014
P2, N=20, Recruiting, Sponsor: Sarepta Therapeutics
- Exondys 51 (eteplirsen) / Sarepta Therap
Trial primary completion date: Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Oct 17, 2014
P2, N=12, Active, not recruiting, Sponsor: Sarepta Therapeutics
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2015 --> Apr 2016
- |||||||||| Exondys 51 (eteplirsen) / Sarepta Therap
New P3 trial: PROMOVI: Study of Eteplirsen in DMD Patients (clinicaltrials.gov) - Oct 2, 2014
P3, N=160, Recruiting, Sponsor: Sarepta Therapeutics
- | Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
Trial completion, Trial primary completion date: Safety Study on IdeS in Healthy Volounteers (clinicaltrials.gov) - Aug 28, 2014
P1, N=29, Completed, Sponsor: Hansa Medical AB
Trial primary completion date: Apr 2015 --> Apr 2016 Recruiting --> Completed | Trial primary completion date: Sep 2013 --> Dec 2013